Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 2 March 2017 Important milestone in Biocartis-Merck collaboration with launch of second liquid biopsy assay Non-regulated information 2 March 2017 Biocartis Announces 2016 Results, 2017 Outlook and change in CEO Position Inside information Regulated information 23 February 2017 Biocartis to host webcast for announcement 2016 financial results on 2 March 2017 Regulated information 22 December 2016 Biocartis submits 510(k) file with US FDA for Idylla™ platform Submission done in parallel with 510(k) submission of Janssen Idylla™ Respiratory (IFV-RSV) Panel Test by Janssen Diagnostics Non-regulated information 22 December 2016 Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe Inside information Regulated information 15 December 2016 CE-marking Idylla™ NRAS-BRAF Mutation Test completes offering of metastatic colorectal cancer tests for clinical use on Idylla™ platform Non-regulated information 14 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 12 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 7 December 2016 Biocartis launches second liquid biopsy assay Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Non-regulated information 28 November 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information Pagination First page « First Previous page ‹‹ … Page 23 Page 24 Page 25 Page 26 Current page 27 Page 28 Page 29 Page 30 Page 31 Next page ›› Last page Last »